Pharmacoeconomics in COPD: Lessons for the future

International Journal of COPD

Volumn 3, Issue 1, 2008, Pages 71-88

  Starkie, Helen J ^a   Briggs, Andrew H ^a   Chambers, Mike G ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Burden of disease; COPD; Cost effectiveness; Economic evaluation; Pharmacoeconomic

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

AGE DISTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION MAKING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FUNDING; HEALTH CARE UTILIZATION; HUMAN; INTERVENTION STUDY; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PATIENT SELECTION; PREVALENCE; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; SMOKING CESSATION; UNCERTAINTY;

COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS;

EID: 42149185054     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Andersson F, Borg S, Jansson SA, et al. 2002. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respiratory Medicine, 96:700-8.
2. Anthonisen N, Skeans MA, Wise RA, et al. 2005. The effects of a smoking cessation intervention on 14.5 year mortality. Annals of Internal Medicine, 142:233-9.
3. Ayres JG, Price MJ, Efthimiou J. 2003. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respiratory Medicine, 97:212-20.
4. Baker CB, Johnsrud MT, Lynn Crismon JM, et al. 2003. Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry, 183:498-506.
5. Baltussen R, Leidl R, Ament A. 1999. Real world designs in economic evaluation: brigding the gap between clinical research and policy-making. Pharmacoeconomics, 16:449-58.
6. Bell CM, Urbach DR, Ray JG, et al. 2006. Bias in published cost effectiveness studies: systematic review. BMJ, 332:699-703.
7. Briggs AH. 2002. Probabilistic analysis of cost-effectiveness odels: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making, 22:290-308.
8. Briggs AH, Lozano-Ortega G, Spencer S, et al. 2006. Estimating the cost-effectiveness of fluticasone propionate for treating chrome obstructive pulmonary disease in the presence of missing data. Value in Health, 9:227-35.
9. Briggs AH, O'Brien BJ. 2001. The death of cost-minimisation analysis? Health Economics, 10:179-84.
10. Britton M. 2003. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respiratory Medicine, 97 Suppl C:S71-9.
11. Calverley PM, Bellamy D. 2000. The challenge of providing better care for patients with chronic obstructive pulmonary disease: the poor relation of airways obstruction? Thorax, 55:78-82.
12. Calverley PM, Sondhi S. 1998. The burden of obstructive lung disease in the UK - COPD and asthma. Thorax, 53 Supp 4:A83.
13. Chapman KR, Bourbeau J, Rance L, et al. 2003. The burden of COPD in Canada: results from the Confronting COPD survey. Respiratory Medicine, 97 Suppl C:S23-31.
14. Claxton K, Sculpher M, Drummond M. 2002. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). The Lancet, 360:711-15.
15. Claxton K, Sculpher M, McCabe C, et al. 2005. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics, 14:339-47.
16. Cook J, Drummond M, Heyes J. 2004. Economic endpoints in clinical trials. Statistical Methods in Medical Research, 13:157-76.
17. Culyer A, McCabe C, Briggs A, et al. 2007. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy, 12:56-8.
18. Dahl R, Greefhorst LA, Nowak D. 2001. Inhaled formoterol dry powder versus ipratroipumbromide in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 164:778-84.
19. Dal Negro R, Rossi A, Cerveri I, et al. 2003. The burden of COPD in Italy: results from the confronting COPD survey. Respiratory Medicine, 97 Suppl C:S43-50.
20. Drummond MF, Sculpher MJ, Torrance GW, et al. 2005. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press.
21. Drummond M, Sculpher M. 2005. Common methodological flaws in economic evaluations. Medical Care, 43(7 Suppl):II5-14.
22. European Respiratory Society and European Lung Foundation. 2003. Chronic obstructive pulmonary disease. In European lung white book. ERSJ, Huddersfield.
23. Fletcher C, Peto R. 1977. The natural history of chronic airflow obstruction. British Medical Journal, 1:1645-8.
24. Friedman MS. C.M. 1999. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest, 115:635-41.
25. Fukuchi Y, Nishimura M, Ichinose M, et al. 2004. COPD in Japan: The Nippon COPD Epidemiology study. Respirology, 9:4.
26. Gagnon YM, Levy AR, Spencer MD, et al. 2005. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. Respiratory Medicine, 99:1534-45.
27. Garber AM. 2000. Advances in cost-effectiveness analysis of health interventions. In: Culyer A, Newhouse J, eds. Handbook of health economics, 1st ed. Amsterdam: Elsevier BV p 181-221.
28. GOLD. 2006. Global initiative for chronic obstructive lung disease.
29. Gold M, Siegel JE, Russel LB, et al. 1996. Cost-effectiveness in health and medicine. New York: Oxford Universty Press.
30. Gross N. 2004. Outcome measures for COPD treatments: a critical evaluation. COPD: Journal of Chronic Obstructive Pulmonary Disease, 1:41-57.
31. Guest JF. 1999. The annual cost of chronic obstructive pulmonary disease to the UK's National Health Service. Disease Management and Health Outcomes, 5:2.
32. Halpern MT, Stanford RH, Borker R, et al. 2003. The burden of COPD in the U.S.A.: results from the Confronting COPD survey. Respiratory Medicine, 97 Suppl C:S81-9.
33. Halpin DM. 2006. Health economics of chronic obstructive pulmonary disease. [Review] [70 refs]. Proceedings of the American Thoracic Society, 3:227-33.
34. Hogan TJ, Geddes R, Gonzalez E. 2003. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clinical Therapeutics, 25:285-97.
35. ISPOR. 2007. Pharmacoeconomic guidelines around the world [online]. URL: http://www.ispor.org/PEguidelines/index.asp
36. Izquierdo JL. 2003. The burden of COPD in Spain: results from the Confronting COPD survey. Respiratory Medicine, 97 Suppl C:S61-9.
37. Jansson SA, Andersson F, Borg S, et al. 2002. Costs of COPD in Sweden according to disease severity. Chest, 122:1994-2002.
38. Jemal A, Ward E, Hao Y, et al. 2005. Trends in the leading causes of death in the United States, 1970-2002. JAMA, 294:14.
39. Jones PW, Wilson KS. 2003. Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respiratory Medicine, 97:20-6.
40. Jubran A, Gross N, Ramsdell J, et al. 1993. Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A three-centre study. Chest, 103:678-84.
41. Lofdahl CG, Ericsson A, Svensson K, et al. 2005. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics, 23:365-75.
42. Lokke A, Lange P, Scharling H, et al. 2006. Developing COPD: a 25 year follow up study of the general population. Thorax, 61:935-9.
43. Lung and Asthma Information Agency. 2003. Trends in COPD [pamphlet]
44. Mackay J, Eriksen M. 2002. The tobacco atlas. World Health Organization
45. Maniadakis N, Tzanakis N, Fragoulakis V, et al. 2006. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Current Medical Research and Opinion, 22:8.
46. McGuire A, Irwin DE, Fenn P, et al. 2001. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value in Health, 4:5.
47. Murray Christopher JL, Lopez AD, Mathers CD, et al. 2001. The Global Burden of Disease 2000 project: aims, methods and data sources. World Health Organization.
48. National Institute for Clinical Excellence. 2004. Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence.
49. National Institute of Health and Clinical Excellence. 2005. A guide to NICE [pamphlet].
50. Oostenbrink JB, Rutten-van Molken MP, Monz BU, et al. 2005. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries [see comment]. Value in Health, 8:32-46.
51. Oostenbrink JB, Rutten-van Molken MP, et al. 2004. One-year cost-effectiveness of tiotropium versus ipratopium to treat chronic obstructive pulmonary disease. European Respiratory Journal, 23(2).
52. Philips Z, Bojke L, Sculpher M, et al. 2006. Good practice guidelines for decision-analytic modelling in Health Technology Assessment: A review and consolidation of quality assessment. Pharmacoeconomics, 24:355-71.
53. Piperno D, Huchon G, Pribil C, et al. 2003. The burden of COPD in France: results from the Confronting COPD survey. Respiratory Medicine, 97(Suppl C):S33-42.
54. Ruchlin HS, Dasbach EJ. 2001. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics, 19(6):
55. Rutten-van Molken M, Lee TA, Authors FN, et al. 2006. Economic modeling in chronic obstructive pulmonary disease. [Review] [15 refs]. Proceedings of the American Thoracic Society, 3:630-4.
56. Rutten-van Molken M, Van Doorslaer EK, Jansen MC, et al. 1995. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 151:975-82.
57. Sculpher M, Claxton K, Drummond M, et al. 2006. Whither trial-based economic evaluation for health care decision making? Health Economics, 15:677-87.
58. Sculpher MJ. 2001. The role and estimation of productivity costs in economic evaluation. In Drummond MF, McGuire A, eds. Theory and practice of economic evaluation in health. Oxford: Oxford University Press.
59. Sin DD, Golmohammadi K, Jacobs P. 2004. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. American Journal of Medicine, 116:325-31.
60. Spencer M, Briggs AH, Grossman RF, et al. 2005. Development of an economic model to assess the cost-effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics, 23:619-37.
61. Sullivan SD. 2003. The burden of illness and economic evaluation for COPD. European Respiratory Journal, 22(Suppl 43):7S-8S.
62. Sullivan SD, Ramsey SD, Lee TA. 2000. The economic burden of COPD. Chest, 117(2 Suppl S):5-9.
63. US Department of Health and Human Services. 2004. Summary health statistics for us adults: National Health Interview Survey, 2004.
64. van den Boom GR. 2001. The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program. American Journal of Respiratory and Critical Care Medicine, 164:2057-66.
65. Wouters EF. 2003. The burden of COPD in The Netherlands: results from the Confronting COPD survey. Respiratory Medicine, 97 Suppl C: S51-9.
66. Yelin E, Katz P, Balmes J. 2006. Work life of persons with asthma, rhinits, and COPD: A study using a national, population based sample. Journal of Occupational Medicine and Toxicology, 1(2).
67. Zielinski J, Bednarek M, Gorecka D, et al. 2006. Increasing COPD awareness. European Respiratory Journal, 27:833-52.